Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective of the study is to evaluate the toxicity profile of combination of herceptin, paclitaxel, carboplatin and gemcitabine in patients with locally recurrent or metastatic urothelial carcinoma who overexpress HER2.
Maha Hussain, MD
Principal Investigator
The University of Michigan Comprehensive Cancer Center
United States: Food and Drug Administration
UMCC 9955
NCT00151034
September 2000
Name | Location |
---|---|
Roswell Park Cancer Institute | Buffalo, New York 14263 |
USC/Norris Comprehensive Cancer Center | Los Angeles, California 90033-0800 |
University of Pennsylvania Cancer Center | Philadelphia, Pennsylvania 19104 |
University of Pittsburgh Cancer Institute | Pittsburgh, Pennsylvania 15213 |
Weill Medical College of Cornell University | New York, New York 10021 |
University of Colorado | Denver, Colorado 80217 |
Wayne State University | Detroit, Michigan 48202 |
Columbia Presbyterian Medical Center | New York, New York 10032 |
The University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan 48109 |
California City of Hope National Medical Group | Duarte, California |
U.C. Davis Medical Center | Sacramento, California |